Drug Shortage Report for TEVA-TRIAMTERENE/HCTZ
Report ID | 118957 |
Drug Identification Number | 00532657 |
Brand name | TEVA-TRIAMTERENE/HCTZ |
Common or Proper name | TRIAMTERENE HCTZ 50/25MG TAB |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | TRIAMTERENE HYDROCHLOROTHIAZIDE |
Strength(s) | 50MG 25MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 100,1000 |
ATC code | C03EA |
ATC description | DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-06-24 |
Estimated end date | 2021-02-28 |
Actual end date | 2021-02-17 |
Shortage status | Resolved |
Updated date | 2021-02-18 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2020-06-25 | French | Compare |
v1 | 2020-06-25 | English | Compare |